Good results for Humira

Abbott has announced that a trial has shown that people for whom Humira (adalimumab) is effective after four weeks who then take Humira either weekly or fortnightly for a year are much more likely to be in remission after six months and after year than those taking a placebo. There's a lot more detail in the press release.

In addition they include interesting news for users of infliximab (Remicade), mentioning:

Abbott has received FDA approval to initiate a Treatment Protocol to study the use of adalimumab in patients no longer responding to or intolerant to infliximab, an approved therapy for Crohn's disease.